Overall, the most frequently mutated drug target genes were BRAF for thyroid cancer, FGFR2 for endometrial cancer, EGFR for brain tumors, MGMT for colorectal cancer, FGFR2 and FGFR3 for bladder cancer, NTRK3 for non-small cell lung cancer and NTRK2, FGFR2, EGFR for stomach cancer. This evidence concerns the gene NTRK2 and endometrial cancer.